395
Views
18
CrossRef citations to date
0
Altmetric
Letters to the Editor

A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia

, , , , , & show all
Pages 2441-2444 | Received 31 Aug 2015, Accepted 28 Dec 2015, Published online: 08 Feb 2016
 

Acknowledgements

The authors thank all the patients and their families for participating in the study, nurses, and clinical research coordinators.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at http://dx.doi.org/10.3109/10428194.2016.1138295.

Funding information

This work was supported by a Specialized Center of Research Program Award (GCNCR0314A-UTAH to M.W.D) from The Leukemia & Lymphoma Society (LLS) and by The V Foundation for Cancer Research (to M.W.D). S.K.T is a recipient of 2013 Research Training Award for Fellows from the American Society of Hematology (ASH). J.S.K is a Special Fellow of the LLS and was supported by a Translational Research Training in Hematology Award from the ASH.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.